Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Oct, 15 2025
Mar, 5 2026
Oct, 8 2025
Aug, 4 2025
Nov, 1 2025